Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319912 · ClinicalTrials.gov registry record · Phase 1
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05319912 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT05319912, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.
Interventions
- DRUG Omeprazole
- DRUG ALXN1840 Enteric-coated Tablet
- DRUG ALXN1840 Non-coated Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-04-07 |
| Est. Completion | 2014-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319912
The ClinicalTrials.gov registry entry for NCT05319912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Omeprazole is the first listed.
NCT05319912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05319912 about?
NCT05319912 is a clinical study titled "A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults". This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.
What is the current status of trial NCT05319912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-04-07. Estimated completion is 2014-05-29.
What interventions are being tested in trial NCT05319912?
The interventions under investigation include: Omeprazole (DRUG), ALXN1840 Enteric-coated Tablet (DRUG), ALXN1840 Non-coated Capsule (DRUG).
Who is sponsoring clinical trial NCT05319912?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.